


| | | | | | | | |
|---|----|---|------------|----------------------------------|--------------|--|--|
| Form PTO-1449 (REV. 8-83) | | US Dept. of Commerce PATENT & TRADEMARK OFFICE | | ATTY DOCKET NO. 109993 | | APPLICATION NO. New U.S. Patent Application | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANT(S) 1636 | | | |
| | | | | FILING DATE December 21, 2001 | | M. Mansch | |
| | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | |
| WNY | 1 | 5.126.433 | 06/30/1992 | Maddon et al. | X | X | |
| MM | 2 | 5.871.913 | 02/16/1999 | Maddon et al. | | | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | |
| MM | 3 | WO 94/19017 | 09/01/1994 | WIPO PCT | X | X | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| MM | 4 | Kamel Sanhadji et al., "Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice", AIDS. pp.2813-2822, Vol. 14, No. 18, 2000 | | | | | |
| MM | 5 | Sarah S. Frankel et al., "Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells", Journal of Virology, pp. 9788-9794, Vol. 72, No. 12, 1998 | | | | | |
| WIM | 6 | Sophie Ugolini et al., "Inhibition of Virus Attachment to CD4 Target Cells Is a Major Mechanism of T Cell Line-adapted HIV-1 Neutralization", J. Exp. Med., pp.1287-1298, Vol. 186, No. 8, 1997 | | | | | |
| WIM | 7 | Nancy Sullivan et al., "CD4-Inducted Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization", Journal of Virology, pp.4694-4703, Vol. 72, No. 6, 1998 | | | | | |
| MM | 8 | Anthony J. Conley et al., "The Consequence of Passive Administration of an Anti-Human Immunodeficiency Virus Type 1 Neutralizing Monoclonal Antibody before Challenge of Chimpanzees with a Primary Virus Isolate", Journal of Virology, pp. 6751-6758, Vol. 70, No. 10, 1996 | | | | | |
| MM | 9 | Anthony J. Conley et al., "Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody", Proc. Natl. Acad. Sci., pp. 3348-3352, Vol. 91, 1994 | | | | | |
| MM | 10 | Alexandra Trkola et al., "Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents is Independent of Coreceptor Usage", Journal of Virology, pp. 1876-1885, Vol. 72, No. 3, 1998 | | | | | |
| MM | 11 | P. J. Klasse et al., "Quantitative Model of Antibody- and Soluble CD4-Mediated Neutralization of Primary Isolates and T-Cell Line-Adapted Strains of Human Immunodeficiency Virus Type 1", Journal of Virology, pp. 3668-3677, Vol. 70, No. 6, 1996 | | | | | |
| MM | 12 | Dominik Schenten et al., "Effects of Soluble CD4 on Simian Immunodeficiency Virus Infection of CD4-Positive and CD4-Negative Cells", Journal of Virology, pp. 5375-5380, Vol. 73, No. 7, 1999 | | | | | |
| EXAMINER M. Mansch | | | | DATE CONSIDERED 3/23/04 | | | |
| Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Sheet 1 of 1

| | | | | | | | |
|---|--|---|-------|---|--------------|-------------------------------|--|
| Form PTO-1449 (REV. 8-83) | | U.S. Dept. of Commerce PATENT & TRADEMARK OFFICE | | ATTY DOCKET NO. 109993 | | APPLICATION NO. 10 024,329 | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary.) | | | | APPLICANT(S) Jean-Louis TOURAINE, et al. | | | |
| | | | | FILING DATE December 21, 2001 | | GROUP 1645 1636 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | |
| <i>MM</i> | | WO 01/55439 A1 | 08/01 | WIPO PCT | X | X | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| EXAMINER <i>MMarrich</i> | | | | DATE CONSIDERED <i>3123/001</i> | | | |
| Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |


Date: April 29, 2002



RECEIVED

Sheet 1 of 4

| | | | | | | | |
|---|--|---|------|--|-------|-------------------------------|--|
| Form PTO-1449 (REV. 8-83) | | U.S. Dept. of Commerce PATENT & TRADEMARK OFFICE | | ATTY DOCKET NO. 109993 | | APPLICATION NO. 10 024 329 | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANT(S) Jean-Louis TOURAINE et al. | | | |
| | | | | FILING DATE December 21, 2001 | | GROUP 1445 1634 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| Wm | | D.D. HO et al., "Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection." <u>Nature</u> , Vol. 373, pp. 123-126, January 1995. | | | | | |
| Wm | | D.D. HO et al., "Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected Persons." <u>The New England Journal of Medicine</u> , Vol. 321, No. 24, pp. 1621-1625, December 1989. | | | | | |
| Wm | | G. PANTALEO et al., "HIV Infection is Active and Progressive in Lymphoid Tissue During the Clinically Latent Stage of Disease." <u>Nature</u> , Vol. 362, pp. 355-358, March 1993. | | | | | |
| Wm | | M. PIATAK, Jr., et al., "High Levels of HIV-1 in Plasma During All Stages of Infection Determined by Competitive PCR." <u>Science</u> , Vol. 259, pp. 1749-1754, March 1993. | | | | | |
| Wm | | J.M. McCUNE et al., "The SCID-hu Mouse: Murine Model for the Analysis of Human Hematolymphoid Differentiation and Function." <u>Science</u> , Vol. 241, pp. 1632-1639, September 1988. | | | | | |
| Wm | | K. SANHADJI et al., "Long-Term Chimera Produced by Transplantation of Human Fetal Liver Cells Into Severe Combined Immunodeficiency Mice." <u>Transplantation Proceedings</u> , Vol. 25, No. 1, pp. 452, February 1993. | | | | | |
| Wm | | R. NAMIKAWA et al., "Infection of the SCID-hu Mouse by HIV-1." <u>Science</u> , Vol. 242, pp. 1684-1686, December 1988. | | | | | |
| Wm | | E.A. EMINI et al., "Prevention of HIV-1 Infection in Chimpanzees by gp120 V3 Domain-Specific Monoclonal Antibody." <u>Nature</u> , Vol. 355, pp. 728-730, February 1992. | | | | | |
| Wm | | G. PANTALEO et al., "Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection." <u>New England Journal of Medicine</u> , Vol. 332, No. 4, pp. 209-216, January 1995. | | | | | |
| Wm | | A. LI et al., "Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins." <u>AIDS Research and Human Retrovirus</u> , Vol. 13, No. 8, pp. 647-656, 1997. | | | | | |
| Wm | | T. SCHACKER et al., "Phase I Study of High-Dose, Intravenous rCD4 in Subjects with Advanced HIV-1 Infection." <u>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</u> , Vol. 9, No. 2, pp. 145-152, 1995. | | | | | |
| Wm | | T.C. MENG et al., "Combination Therapy with Recombinant Human Soluble CD4-Immunoglobulin G and Zidovudine in Patients with HIV Infection: A Phase I Study." <u>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</u> , Vol. 8, No. 2, pp. 152-160, 1995. | | | | | |
| Wm | | R.A. MORGAN et al., "Further Evaluation of Soluble CD4 as an Anti-HIV Type 1 Gene Therapy: Demonstration of Protection of Primary Human Peripheral Blood Lymphocytes from Infection by HIV Type 1." <u>AIDS Research and Human Retroviruses</u> , Vol. 10, No. 11, pp. 1507-1515, 1994. | | | | | |
| Wm | | T. MUSTER et al., "A Conserved Neutralizing Epitope on gp41 of Human Immunodeficiency Virus Type 1." <u>Journal of Virology</u> , Vol. 67, No. 11, pp. 6642-6647, November 1993. | | | | | |
| EXAMINER Wm | | | | DATE CONSIDERED 3/23/04 | | | |
| Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |




RECEIVED

Sheet 2 of 4

TECH CENTER 1800 2800

| | | | | | | | |
|---|--|--|------|--|-------|-------------------------------|--|
| Form PTO-1449 (REV. 8-83) | | U.S. Dept. of Commerce PATENT & TRADEMARK OFFICE | | ATTY DOCKET NO. 109993 | | APPLICATION NO. 10 024,329 | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANT(S) Jean-Louis TOURAINE et al. | | | |
| | | | | FILING DATE December 21, 2001 | | GROUP 1645 1636 | |
| | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| MM | | P.L. NARA et al., "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection Human Immunodeficiency Virus Neutralizing Antibody," <u>AIDS Research and Human Retroviruses</u> , Vol. 3, No. 3, pp. 283-302, 1987. | | | | | |
| MM | | A. BUCHACHER et al., "Generation of Human Monoclonal Antibodies Against HIV-1 Proteins: Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization," <u>AIDS Research and Human Retroviruses</u> , Vol. 10, No. 4, pp. 359-369, 1994. | | | | | |
| MM | | T. MUSTER et al., "Cross-Neutralizing Activity Against Divergent Human Immunodeficiency Virus Type 1 Isolates Induced by the gp41 Sequence ELDKWAS," <u>Journal of Virology</u> , Vol. 68, No. 6, pp. 4031-4034, June 1994. | | | | | |
| MM | | P. W.H.I. PARREN et al., "Protection Against HIV-1 Infection in hu-PBL-SCID Mice by Passive Immunization with a Neutralizing Human Monoclonal Antibody Against the gp120 CD4-binding Site," <u>AIDS</u> , Vol. 9, No. 6, pp. F1-F6, 1995. | | | | | |
| MM | | L. ANDRUS, et al., "Passive Immunization with a Human Immunodeficiency Virus Type 1-Neutralizing Monoclonal Antibody in Hu-PDL-SCID Mice: Isolation of a Neutralization Escape Variant," <u>Journal of Infectious Disease</u> , Vol. 177, pp. 889-897, April 1998. | | | | | |
| MM | | D.H. SMITH et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen," <u>Science</u> , Vol. 238 pp. 1704-1707, December 1987. | | | | | |
| MM | | K. C. DEEN et al., "A Soluble Form of CD4 (T4) Protein Inhibits AIDS Virus Infection," <u>Nature</u> , Vol. 331, pp. 82-84 January 1988. | | | | | |
| MM | | R.A. BYRN et al., "Characterization of In Vitro Inhibition of Human Immunodeficiency Virus by Purified Recombinant CD4," <u>Journal of Virology</u> , Vol. 63, No. 10, pp. 4370-4375, October 1989. | | | | | |
| MM | | D.J. CAPON et al., "Designing CD4 Immunoconjugates for AIDS Therapy," <u>Nature</u> , Vol. 337, pp. 525-531, February 1989. | | | | | |
| MM | | G.P. ALLAWAY et al., "Expression and Characterization of CD4-IgG ₂ , A Novel Heterotetramer that Neutralizes Primary HIV Type 1 Isolates," <u>AIDS Research and Human Retroviruses</u> , Vol. 11, No. 5, pp. 533-539, 1995. | | | | | |
| MM | | H. TSUBOTA et al., "CD4-Pseudomonas Exotoxin Conjugates Delay but Do Not Fully Inhibit Human Immunodeficiency Virus Replication in Lymphocytes in Vitro," <u>J. Clin. Invest.</u> , Vol. 86, pp. 1684-1689, November 1990. | | | | | |
| MM | | S. DEMARIA et al., "Soluble CD4 Induces the Binding of Human Immunodeficiency Virus Type 1 to Cells via the V3 Loop of Glycoprotein 120 and Specific Sites in Glycoprotein 41," <u>AIDS Research and Human Retroviruses</u> , Vol. 12, No. 4, pp. 281-290, 1996. | | | | | |
| MM | | Q.J. SATTENTAU et al., "Epitope Exposure on Functional, Oligomeric HIV-1 gp41 Molecules," <u>Virology</u> , Vol. 206, pp. 713-717, 1995. | | | | | |
| EXAMINER M. Mannich | | | | DATE CONSIDERED 3/23/04 | | | |
| Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Date: June 4, 2002




RECEIVED

TECHNICAL SHEET 3 of 4

| | | | | | | | |
|---|--|---|------|--|-------|-------------------------------|--|
| Form PTO-1449 (REV. 8-83) | | U.S. Dept. of Commerce PATENT & TRADEMARK OFFICE | | ATTY DOCKET NO. 109993 | | APPLICATION NO. 10 024.329 | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANT(S) Jean-Louis TOURAINE et al. | | | |
| | | | | FILING DATE December 21, 2001 | | GROUP 1645 1636 | |
| | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| MM | | E. SHINYA et al., "In-Vivo Delivery of Therapeutic Proteins by Genetically-Modified Cells: Comparison of Organoids and Human Serum Albumin Alginate-Coated Beads," <u>Bioméd & Pharmacother.</u> Vol. 53, pp. 471-483, 1999. | | | | | |
| MM | | F. BARRE-SINOUSSE et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," <u>Science</u> , Vol. 220, pp. 868-870, May 1983. | | | | | |
| MM | | R.C. GALLO et al., "Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS," <u>Science</u> , Vol. 224, pp. 500-503, May 1984. | | | | | |
| MM | | S. WAIN-HOBSON et al., "Nucleotide Sequence of the AIDS Virus, LAV," <u>Cell</u> , Vol. 40, pp. 9-17, January 1985. | | | | | |
| MM | | L. RATNER et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III," <u>Nature</u> , Vol. 313, pp. 277-284, January 1985. | | | | | |
| MM | | H. KATINGER et al., "Results of Preclinical Screening and Epitope Mapping of Human Monoclonal Antibodies Against HIV-1," <u>Septieme Colloque Des Cant Gardes</u> , Vienna, Austria, pp. 299-303, 1992. | | | | | |
| MM | | P.D. ROBBINS et al., "Viral Vectors for Gene Therapy," <u>TibTech</u> , Vol. 16, pp. 35-40, January 1998. | | | | | |
| MM | | P.L. FELGNER et al., "Cationic Liposome Mediated Transfection," <u>Proc. West. Pharmacol. Soc.</u> Vol. 32, pp. 115-121, 1989. | | | | | |
| MM | | C.P. HODGSON et al., "Virosoemes: Cationic Liposomes Enhance Retroviral Transduction," <u>Nature Biotechnology</u> , Vol. 14, pp. 339-342, March 1996. | | | | | |
| MM | | J. REMY et al., "Gene Transfer with a Series of Lipophilic DNA-Binding Molecules," <u>Bioconjugate Chem.</u> , Vol. 5, No. 6 pp. 647-654, 1994. | | | | | |
| MM | | R. LATHE et al., "Plasmid and Bacteriophage Vectors for Excision of Intact Inserts," <u>Gene</u> , Vol. 57, pp. 193-201, 1987. | | | | | |
| MM | | S. LUPTON et al., "Mapping Genetic Elements of Epstein-Barr Virus that Facilitate Extrachromosomal Persistence of Epstein-Barr Virus-Derived Plasmids in Human Cells," <u>Molecular and Cellular Biology</u> , Vol. 5, No. 10, pp. 2533-2542, October 1985. | | | | | |
| MM | | J.L. YATES et al., "Stable Replication of Plasmids Derived from Epstein-Barr Virus in Various Mammalian Cells," <u>Nature</u> , Vol. 313, pp. 812-815, February 1985. | | | | | |
| MM | | D.K. SUMMERS et al., "Multimerization of High Copy Number Plasmids Causes Instability: ColEI Encodes a Determinant Essential for Plasmid Monomerization and Stability," <u>Cell</u> , Vol. 36, pp. 1097-1103, April 1984. | | | | | |
| EXAMINER M Marvich | | | | DATE CONSIDERED 3/23/04 | | | |
| Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Date: June 4, 2002



| | | | | | | | |
|---|--|---|------|--|-------|-------------------------------|--|
| Form PTO-1449 (REV. 8-83) | | US Dept. of Commerce PATENT & TRADEMARK OFFICE | | ATTY DOCKET NO. 109993 | | APPLICATION NO. 10 024,329 | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANT(S) Jean-Louis TOURAINE et al. | | | |
| | | | | FILING DATE December 21, 2001 | | GROUP 1636 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| MM | | N. CHINNASAMY et al., "Efficient Gene Transfer to Human Peripheral Blood Monocyte-Derived Dendritic Cells Using Human Immunodeficiency Virus Type 1-Based Lentiviral Vectors." <u>Human Gene Therapy</u> , Vol. 11, pp. 1901-1909, September 2000. | | | | | |
| MM | | M.D. BROWN et al., "Gene Delivery with Synthetic (non viral) Carriers." <u>International Journal of Pharmaceutics</u> , Vol. 229 pp. 1-21, 2001. | | | | | |
| MM | | F.L. GRAHAM et al., "Manipulation of Adenovirus Vectors." <u>Methods of Molecular Biology</u> , Vol. 7, pp. 109-128, 1991. | | | | | |
| MM | | A.N. ZAKHARCHUK et al., "Physical Mapping and Homology Studies of Egg Drop Syndrome (EDS-76) Adenovirus DNA." <u>Archives of Virology</u> , Vol. 128, pp. 171-176, 1993. | | | | | |
| MM | | N. SPIBEY et al., "Molecular Cloning and Restriction Endonuclease Mapping of Two Strains of Canine Adenovirus Type 2." <u>J. Gen. Virol.</u> , Vol. 70, pp. 165-172, 1989. | | | | | |
| MM | | P. JOUVENNE et al., "Cloning, Physical Mapping and Cross-Hybridization of the Canine Adenovirus Types 1 and 2 Genomes." <u>Gene</u> , Vol. 60, pp. 21-28, 1987. | | | | | |
| MM | | S.K. MITTAL et al., "Development of a Bovine Adenovirus Type 3-based Expression Vector." <u>Journal of General Virology</u> , Vol. 76, pp. 93-102, 1995. | | | | | |
| MM | | C.J. TABIN et al., "Adaptation of a Retrovirus as a Eucaryotic Vector Transmitting the Herpes Simplex Virus Thymidine Kinase Gene." <u>Molecular and Cellular Biology</u> , Vol. 2, No. 4, pp. 426-436, April 1982. | | | | | |
| MM | | Y. TAKEBE et al., "SR α Promoter: an Efficient and Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat." <u>Molecular and Cellular Biology</u> , Vol. 8, No. 1, pp. 466-472, January 1988. | | | | | |
| MM | | L. CHEN et al., "Breast Cancer Selective Gene Expression and Therapy Mediated by Recombinant Adenoviruses Containing the DF3/MUC1 Promoter." <u>J. Clin. Invest.</u> , Vol. 96, pp. 2775-2782, December 1995. | | | | | |
| MM | | H. SCHREWE et al., "Cloning of the Complete Gene for Carcinoembryonic Antigen: Analysis of its Promoter Indicates a Region Conveying Cell Type-Specific Expression." <u>Molecular and Cellular Biology</u> , Vol. 10, No. 6, pp. 2738-2748, June 1990. | | | | | |
| MM | | R.G. VILE et al., "Use of Tissue-specific Expression of the Herpes Simplex Virus Thymidine Kinase Gene to Inhibit Growth of Established Murine Melanomas Following Direct Intratumoral Injection of DNA." <u>Cancer Research</u> , Vol. 53, pp. 3860-3864, September 1993. | | | | | |
| MM | | J.D. HARRIS et al., "Gene Therapy for Cancer using Tumor-specific Prodrug Activation." <u>Gene Therapy</u> , Vol. 1, pp. 170-175, 1994. | | | | | |
| MM | | F. KANAI et al., "In Vivo Gene Therapy for α -Fetoprotein-producing Hepatocellular Carcinoma by Adenovirus-mediated Transfer of Cytosine Deaminase Gene." <u>Cancer Research</u> , Vol. 57, pp. 461-465, February 1997. | | | | | |
| MM | | R.S. McIVOR et al., "Human Purine Nucleoside Phosphorylase and Adenosine Deaminase: Gene Transfer into Cultured Cells and Murine Hematopoietic Stem Cells by Using Recombinant Amphotropic Retroviruses." <u>Molecular and Cellular Biology</u> , Vol. 7, No. 2, pp. 838-846, February 1987. | | | | | |
| EXAMINER M. Mansel | | | | DATE CONSIDERED 3/23/04 | | | |
| Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

JUN 10 2002

TRADEMARK OFFICE

Sheet 1 of 1

Form PTO-1447
(REV. 8-83)U.S. Dept. of Commerce
PATENT & TRADEMARK OFFICEATTY DOCKET NO.
109993APPLICATION
10 024,329

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT(S)

Jean-Louis TOURAINE et al.

FILING DATE

December 21, 2001

GROUP

1648-1636

TECH CENTER 1600 2900

JUN 14 2002

RECEIVED

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS |
|---------------------|-----------------|-------|----------------|--------------|--------------|
| | 5,817,767 | 10 98 | ALLAWAY et al. | X | X |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS |
|-----------------|-------|--------------------|--------------|--------------|
| WO 94 19017 | 09 94 | ALLAWAY et al. PCT | X | X |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

| | |
|----|--|
| mm | D.R. KLATZMANN et al., "The CD4 Molecule and HIV Infection," <u>Immunodeficiency Reviews</u> , Vol. 2, pp. 43-66, 1990. |
| mm | T. VALERE et al., "Continuous Secretion of Human Soluble CD4 in Mice Transplanted with Genetically Modified Cells," <u>Gene Therapy</u> , Vol. 2, pp. 197-202, 1995. |
| mm | D.R. KLATZMANN et al., "T-lymphocyte T4 Molecule Behaves as the Receptor for Human Retrovirus LAV," <u>Nature</u> , Vol. 312, pp. 767-768, December 1984. |
| mm | J.A. WOLFF et al., "Direct Gene Transfer into Mouse Muscle in Vivo," <u>Science</u> , Vol. 247, pp. 1465-1468, March 1990. |
| | |
| | |
| | |

EXAMINER

mmmmmm

DATE CONSIDERED

3/23/02

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: June 10, 2002

